Daratumumab (anti-CD38) induces loss of CD38 on red blood cells whom HCT-CI appeared to be crucially important was the group of patients at high risk for disease relapse (beyond CR1/CR2 or with high-risk cytogenetics). A high HCT-CI in these patients resulted in uniformly negative outcomes. This group of patients with very poor prognosis should probably not be transplanted. Lastly, the intermediaterisk group could be the group that would benefit the most from posttransplant interventions to decrease relapse rate. This analysis is limited by a relatively small number of patients treated with haploidentical transplants only. Factors included in the risk model were selected from significant factors identified in the multivariable model for PFS without weighting of the prognostic impact of each component. This model needs to be validated in a larger number of patients, including HLA-matched transplants, as it could have major implications in treatment decisions. In conclusion, risk stratification models combining disease and patient characteristics could further refine prognosis for potential ASCT patients, better identify patients who could benefit from maintenance therapies posttransplant, as well as serve as a tool to further compare results among different studies.